+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Endometrial Cancer"

Oncology Biomarkers: Global Markets - Product Thumbnail Image

Oncology Biomarkers: Global Markets

  • Report
  • June 2023
  • 186 Pages
  • Global
From
From
From
Neoplasia and Fertility - Product Thumbnail Image

Neoplasia and Fertility

  • Book
  • September 2022
From
Oncology Market Forecast (2020-2025) - Product Thumbnail Image

Oncology Market Forecast (2020-2025)

  • Report
  • August 2020
  • 142 Pages
  • Global
From
Oncology. Edition No. 1. Mount Sinai Expert Guides - Product Thumbnail Image

Oncology. Edition No. 1. Mount Sinai Expert Guides

  • Book
  • October 2019
  • 632 Pages
Oncology. Edition No. 3. Lecture Notes - Product Thumbnail Image

Oncology. Edition No. 3. Lecture Notes

  • Book
  • January 2016
  • 368 Pages
  • 17 Results (Page 1 of 1)
Loading Indicator

Endometrial cancer is a type of cancer that affects the lining of the uterus. It is the most common gynecologic cancer in the United States, and is typically diagnosed in women over the age of 50. Symptoms of endometrial cancer include abnormal vaginal bleeding, pelvic pain, and pain during intercourse. Treatment options for endometrial cancer include surgery, radiation therapy, chemotherapy, and hormone therapy. The oncology market for endometrial cancer is highly competitive, with a range of treatments available. Pharmaceutical companies are developing new drugs to target endometrial cancer, and medical device companies are developing new technologies to improve diagnosis and treatment. Additionally, research is being conducted to better understand the biology of endometrial cancer and to develop new treatments. Companies in the endometrial cancer market include AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more